Cipla Limited, together with its subsidiaries, engages in the manufacture, development, sale, and distribution of pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney failure, Alzheimer’s disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women’s health, ophthalmology, and neuro psychiatry. The company is also involved in the consumer healthcare, biosimilars, and specialty businesses. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.
Metrics to compare | CIPL | Peers Peers - average of corresponding metrics from companies closely matching CIPL: LUPIN, TORNTPHARM, IPCALAB, PFIZER, 531739 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCIPLPeersSector |
---|---|---|---|---|
P/E Ratio | 26.3x | 35.8x | −0.6x | |
PEG Ratio | 0.89 | 1.44 | 0.00 | |
Price/Book | 4.1x | 5.2x | 2.6x | |
Price / LTM Sales | 4.5x | 4.6x | 3.2x | |
Upside (Analyst Target) | 14.3% | 9.0% | 40.6% | |
Fair Value Upside | Unlock | −18.4% | 7.1% | Unlock |